Compare Blue Owl Capital Inc. Class A Common Stock (OWL) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blue Owl Capital Inc. Class A Common Stock vs Health Care Select Sector SPDR Fund — how do they compare? Blue Owl Capital Inc. Class A Common Stock trades at $8.86 (market cap $6.01B), while Health Care Select Sector SPDR Fund trades at $176.22 (market cap $43.92B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 7.3× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 10.35% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Blue Owl Capital Inc. Class A Common Stock for 0 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| OWL | XLV | |
|---|---|---|
Market Cap | $6.01B | $43.92B |
Volume | 24,327,195 | 11,816,834 |
Sector | Financials | — |
52-Week High | $17.17 | $175.68 |
52-Week Low | $8.23 | $142.33 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $10.19B | — |
Dividend Yield | 10.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
XLV trades at $169.66, down 1.35% today, while maintaining a bullish technical outlook with strong moving average signals. The healthcare ETF's low 0.08% expense ratio and diversified exposure to 61 S&P 500 healthcare stocks provide cost-effective sector access. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and political volatility.
Outlook remains positive given healthcare's defensive positioning amid economic uncertainty, though overbought RSI levels suggest near-term consolidation. Key risks include sector-specific regulatory pressures and election-related policy uncertainty that could impact healthcare stocks through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
